201 related articles for article (PubMed ID: 30714241)
1. 18F-Florbetaben PET/CT to Assess Alzheimer's Disease: A new Analysis Method for Regional Amyloid Quantification.
Alongi P; Sardina DS; Coppola R; Scalisi S; Puglisi V; Arnone A; Raimondo GD; Munerati E; Alaimo V; Midiri F; Russo G; Stefano A; Giugno R; Piccoli T; Midiri M; Grimaldi LME
J Neuroimaging; 2019 May; 29(3):383-393. PubMed ID: 30714241
[TBL] [Abstract][Full Text] [Related]
2. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
[TBL] [Abstract][Full Text] [Related]
3. Use of amyloid PET/CT with
Ferrari C; Caputo P; Pisani AR; Nappi AG; Branca A; Lavelli V; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():142-152. PubMed ID: 31802055
[TBL] [Abstract][Full Text] [Related]
4. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
[TBL] [Abstract][Full Text] [Related]
5. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
[TBL] [Abstract][Full Text] [Related]
6. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
7. Clinical Relevance of [
Librizzi D; Cabanel N; Zavorotnyy M; Riehl E; Kircher T; Luster M; Hooshyar Yousefi B
Molecules; 2021 Feb; 26(5):. PubMed ID: 33652938
[TBL] [Abstract][Full Text] [Related]
8. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of early-phase [
Daerr S; Brendel M; Zach C; Mille E; Schilling D; Zacherl MJ; Bürger K; Danek A; Pogarell O; Schildan A; Patt M; Barthel H; Sabri O; Bartenstein P; Rominger A
Neuroimage Clin; 2017; 14():77-86. PubMed ID: 28138429
[TBL] [Abstract][Full Text] [Related]
10. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
11. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
12. [
Stenzel J; Rühlmann C; Lindner T; Polei S; Teipel S; Kurth J; Rominger A; Krause BJ; Vollmar B; Kuhla A
Curr Alzheimer Res; 2019; 16(1):49-55. PubMed ID: 30345916
[TBL] [Abstract][Full Text] [Related]
13. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI.
Akamatsu G; Ikari Y; Ohnishi A; Nishida H; Aita K; Sasaki M; Yamamoto Y; Sasaki M; Senda M
Phys Med Biol; 2016 Aug; 61(15):5768-80. PubMed ID: 27405579
[TBL] [Abstract][Full Text] [Related]
14. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
15. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
Sabri O; Sabbagh MN; Seibyl J; Barthel H; Akatsu H; Ouchi Y; Senda K; Murayama S; Ishii K; Takao M; Beach TG; Rowe CC; Leverenz JB; Ghetti B; Ironside JW; Catafau AM; Stephens AW; Mueller A; Koglin N; Hoffmann A; Roth K; Reininger C; Schulz-Schaeffer WJ;
Alzheimers Dement; 2015 Aug; 11(8):964-74. PubMed ID: 25824567
[TBL] [Abstract][Full Text] [Related]
16. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.
Villemagne VL; Ong K; Mulligan RS; Holl G; Pejoska S; Jones G; O'Keefe G; Ackerman U; Tochon-Danguy H; Chan JG; Reininger CB; Fels L; Putz B; Rohde B; Masters CL; Rowe CC
J Nucl Med; 2011 Aug; 52(8):1210-7. PubMed ID: 21764791
[TBL] [Abstract][Full Text] [Related]
17. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
[TBL] [Abstract][Full Text] [Related]
18. Early detection of amyloid load using
Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
[TBL] [Abstract][Full Text] [Related]
19. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
20. Assessment of 18F-Florbetaben Amyloid PET Imaging in Patients with Suspected Alzheimer's Disease and Isolated Increase in Cerebrospinal Fluid Tau Proteins.
Manca C; Hopes L; Kearney-Schwartz A; Roch V; Karcher G; Baumann C; Marie PY; Malaplate-Armand C; Jonveaux TR; Verger A
J Alzheimers Dis; 2019; 68(3):1061-1069. PubMed ID: 30883358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
